ChemPartner, a China-based global contract research organisation (CRO) serving the biopharmaceutical industry, announced on Thursday the introduction of an updated visual identity and improved digital experience.
According to ChemPartner, this evolution clarifies its visual and verbal expression to better reflect its collaborative spirit and scalable expertise.
ChemPartner's refreshed digital experience at chempartner.com is designed to offer intuitive navigation to end-to-end capabilities, from discovery chemistry and biologics to DMPK and CMC. The site highlights real-world case studies, data and scientists behind the work, enabling visitors to easily explore and connect ChemPartner's expertise to their research goals.
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA
ABL Bio receives upfront payment and equity investment from Eli Lilly
CARsgen Therapeutics submits two IND applications for CT0596 to Chinese regulator
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development